 Edward Stenehjem
Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 14 | 2024 | 100 | 5.490 |
Why?
| | Hospitals, Community | 7 | 2023 | 50 | 3.020 |
Why?
| | Anti-Bacterial Agents | 22 | 2024 | 1701 | 2.170 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 6 | 2015 | 216 | 1.480 |
Why?
| | Carrier State | 4 | 2015 | 60 | 1.320 |
Why?
| | Staphylococcal Infections | 5 | 2015 | 385 | 1.290 |
Why?
| | Cross Infection | 6 | 2020 | 203 | 1.190 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 372 | 1.120 |
Why?
| | Ambulatory Care | 9 | 2023 | 509 | 0.770 |
Why?
| | Sinusitis | 1 | 2023 | 204 | 0.700 |
Why?
| | Hospitalization | 16 | 2024 | 2080 | 0.690 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 67 | 0.610 |
Why?
| | Anti-Infective Agents | 2 | 2018 | 246 | 0.580 |
Why?
| | Influenza Vaccines | 4 | 2023 | 544 | 0.560 |
Why?
| | Health Plan Implementation | 1 | 2018 | 137 | 0.560 |
Why?
| | Nasal Cavity | 2 | 2015 | 53 | 0.510 |
Why?
| | Practice Patterns, Physicians' | 6 | 2023 | 1281 | 0.510 |
Why?
| | Community-Acquired Infections | 3 | 2017 | 153 | 0.500 |
Why?
| | Drug Utilization | 1 | 2016 | 169 | 0.500 |
Why?
| | Humans | 63 | 2025 | 128896 | 0.470 |
Why?
| | Veterans | 3 | 2015 | 1397 | 0.440 |
Why?
| | Population Surveillance | 2 | 2015 | 428 | 0.420 |
Why?
| | Inappropriate Prescribing | 3 | 2023 | 54 | 0.410 |
Why?
| | Asymptomatic Infections | 1 | 2012 | 23 | 0.410 |
Why?
| | Influenza, Human | 3 | 2023 | 603 | 0.400 |
Why?
| | Ventriculostomy | 1 | 2012 | 22 | 0.390 |
Why?
| | Drug Resistance, Bacterial | 6 | 2020 | 170 | 0.390 |
Why?
| | Bacteriological Techniques | 1 | 2012 | 69 | 0.380 |
Why?
| | Adult | 29 | 2024 | 35361 | 0.380 |
Why?
| | Utah | 4 | 2024 | 64 | 0.380 |
Why?
| | Mycoses | 1 | 2012 | 70 | 0.370 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 129 | 0.370 |
Why?
| | Bacterial Infections | 2 | 2019 | 236 | 0.370 |
Why?
| | Central Nervous System Diseases | 1 | 2012 | 68 | 0.370 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2012 | 93 | 0.370 |
Why?
| | Prostheses and Implants | 1 | 2012 | 140 | 0.350 |
Why?
| | Sepsis | 3 | 2024 | 561 | 0.350 |
Why?
| | Emergency Service, Hospital | 11 | 2024 | 1977 | 0.340 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1045 | 0.320 |
Why?
| | RNA, Messenger | 7 | 2024 | 2700 | 0.310 |
Why?
| | Outpatients | 2 | 2023 | 366 | 0.310 |
Why?
| | Idaho | 2 | 2018 | 14 | 0.290 |
Why?
| | Immunization, Secondary | 3 | 2022 | 88 | 0.280 |
Why?
| | United States | 14 | 2023 | 13975 | 0.270 |
Why?
| | Delivery of Health Care | 3 | 2023 | 896 | 0.270 |
Why?
| | Ambulatory Care Facilities | 3 | 2021 | 226 | 0.270 |
Why?
| | Research Design | 2 | 2025 | 1038 | 0.260 |
Why?
| | Vaccination | 6 | 2024 | 1350 | 0.260 |
Why?
| | Middle Aged | 20 | 2024 | 30977 | 0.250 |
Why?
| | Hospitals | 4 | 2023 | 628 | 0.240 |
Why?
| | Candidemia | 1 | 2024 | 9 | 0.240 |
Why?
| | Aged, 80 and over | 9 | 2024 | 7050 | 0.240 |
Why?
| | Candida | 1 | 2024 | 37 | 0.240 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 112 | 0.230 |
Why?
| | Aged | 16 | 2024 | 22035 | 0.230 |
Why?
| | Laboratories | 2 | 2021 | 102 | 0.220 |
Why?
| | Telemedicine | 2 | 2024 | 773 | 0.210 |
Why?
| | Hospitals, Veterans | 2 | 2015 | 264 | 0.200 |
Why?
| | Male | 21 | 2024 | 63146 | 0.200 |
Why?
| | Viral Vaccines | 1 | 2023 | 93 | 0.200 |
Why?
| | Female | 21 | 2024 | 68162 | 0.200 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2023 | 145 | 0.190 |
Why?
| | Adolescent | 12 | 2024 | 20197 | 0.190 |
Why?
| | Case-Control Studies | 6 | 2023 | 3334 | 0.180 |
Why?
| | Language | 1 | 2023 | 283 | 0.180 |
Why?
| | Cohort Studies | 3 | 2023 | 5394 | 0.180 |
Why?
| | Immunocompromised Host | 1 | 2021 | 198 | 0.170 |
Why?
| | Checklist | 2 | 2018 | 99 | 0.170 |
Why?
| | Clostridium Infections | 1 | 2020 | 57 | 0.160 |
Why?
| | Cooperative Behavior | 2 | 2020 | 427 | 0.160 |
Why?
| | Risk Factors | 7 | 2024 | 9792 | 0.160 |
Why?
| | Community-Based Participatory Research | 1 | 2020 | 145 | 0.160 |
Why?
| | Vaccines, Combined | 3 | 2023 | 48 | 0.160 |
Why?
| | Hospital Bed Capacity | 1 | 2018 | 24 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 334 | 0.150 |
Why?
| | Retrospective Studies | 7 | 2024 | 14546 | 0.150 |
Why?
| | Drug Utilization Review | 1 | 2018 | 57 | 0.150 |
Why?
| | Immunization | 1 | 2020 | 416 | 0.150 |
Why?
| | Inservice Training | 1 | 2018 | 113 | 0.140 |
Why?
| | Random Allocation | 1 | 2018 | 351 | 0.140 |
Why?
| | Young Adult | 6 | 2024 | 12286 | 0.140 |
Why?
| | Health Services Research | 1 | 2020 | 392 | 0.140 |
Why?
| | Cluster Analysis | 1 | 2018 | 479 | 0.140 |
Why?
| | Mass Screening | 3 | 2013 | 1121 | 0.130 |
Why?
| | Documentation | 1 | 2018 | 182 | 0.130 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 516 | 0.130 |
Why?
| | Pharmacists | 1 | 2018 | 259 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2019 | 859 | 0.120 |
Why?
| | Patient Readmission | 2 | 2021 | 674 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1024 | 0.120 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 20 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 361 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 355 | 0.120 |
Why?
| | Molecular Epidemiology | 1 | 2015 | 62 | 0.120 |
Why?
| | Leadership | 1 | 2018 | 356 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 846 | 0.110 |
Why?
| | Hospital Mortality | 3 | 2023 | 853 | 0.110 |
Why?
| | Program Evaluation | 1 | 2018 | 868 | 0.110 |
Why?
| | Prospective Studies | 7 | 2022 | 7060 | 0.110 |
Why?
| | Isoniazid | 1 | 2013 | 59 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5032 | 0.110 |
Why?
| | Vitamin D Deficiency | 1 | 2015 | 179 | 0.100 |
Why?
| | Intensive Care Units | 2 | 2021 | 730 | 0.100 |
Why?
| | Medical Staff, Hospital | 1 | 2013 | 79 | 0.100 |
Why?
| | Georgia | 1 | 2012 | 79 | 0.100 |
Why?
| | Bacterial Load | 1 | 2012 | 67 | 0.100 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2013 | 135 | 0.100 |
Why?
| | Infection Control | 1 | 2013 | 138 | 0.100 |
Why?
| | Coinfection | 1 | 2013 | 130 | 0.100 |
Why?
| | Primary Prevention | 1 | 2013 | 191 | 0.100 |
Why?
| | Antitubercular Agents | 1 | 2013 | 195 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2015 | 201 | 0.100 |
Why?
| | Nursing Staff, Hospital | 1 | 2013 | 149 | 0.090 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 68 | 0.090 |
Why?
| | Prostatic Neoplasms | 2 | 2017 | 995 | 0.090 |
Why?
| | Pneumonia | 1 | 2017 | 612 | 0.090 |
Why?
| | Gram-Negative Bacteria | 1 | 2011 | 70 | 0.090 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2011 | 44 | 0.090 |
Why?
| | Logistic Models | 3 | 2025 | 1963 | 0.090 |
Why?
| | Tuberculosis | 1 | 2013 | 271 | 0.090 |
Why?
| | Deep Brain Stimulation | 1 | 2012 | 96 | 0.090 |
Why?
| | Risk | 1 | 2012 | 866 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2013 | 312 | 0.080 |
Why?
| | Virulence Factors | 1 | 2011 | 151 | 0.080 |
Why?
| | Recurrence | 1 | 2012 | 1013 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2013 | 1264 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2668 | 0.070 |
Why?
| | Models, Biological | 1 | 2014 | 1702 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1840 | 0.070 |
Why?
| | Incidence | 1 | 2012 | 2634 | 0.060 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.060 |
Why?
| | Child, Preschool | 4 | 2023 | 10457 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 5 | 0.060 |
Why?
| | Ethiopia | 2 | 2013 | 35 | 0.060 |
Why?
| | Child | 6 | 2023 | 20824 | 0.060 |
Why?
| | Propensity Score | 1 | 2025 | 262 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2023 | 43 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2024 | 255 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 1967 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 182 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 11 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 861 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 77 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1221 | 0.050 |
Why?
| | Seasons | 1 | 2023 | 502 | 0.040 |
Why?
| | Contraindications | 1 | 2020 | 90 | 0.040 |
Why?
| | Computer Simulation | 1 | 2025 | 943 | 0.040 |
Why?
| | Clindamycin | 1 | 2020 | 13 | 0.040 |
Why?
| | Carbapenems | 1 | 2020 | 16 | 0.040 |
Why?
| | Daptomycin | 1 | 2020 | 17 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 197 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2020 | 45 | 0.040 |
Why?
| | Doxycycline | 1 | 2020 | 57 | 0.040 |
Why?
| | Cephalosporins | 1 | 2020 | 39 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1545 | 0.040 |
Why?
| | Risk Assessment | 2 | 2022 | 3286 | 0.040 |
Why?
| | Policy | 1 | 2020 | 144 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2696 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 206 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2019 | 253 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 642 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 708 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5355 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2020 | 610 | 0.030 |
Why?
| | Clinical Audit | 1 | 2015 | 10 | 0.030 |
Why?
| | Mortality | 1 | 2017 | 310 | 0.030 |
Why?
| | Electronic Mail | 1 | 2015 | 61 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 783 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1019 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2015 | 306 | 0.030 |
Why?
| | Hand Sanitizers | 1 | 2013 | 2 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2013 | 8 | 0.030 |
Why?
| | Hand Dermatoses | 1 | 2013 | 7 | 0.030 |
Why?
| | Patient Isolation | 1 | 2013 | 16 | 0.030 |
Why?
| | World Health Organization | 1 | 2013 | 106 | 0.030 |
Why?
| | Masks | 1 | 2013 | 59 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1504 | 0.030 |
Why?
| | Time Factors | 2 | 2022 | 6568 | 0.020 |
Why?
| | Reminder Systems | 1 | 2013 | 173 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1516 | 0.020 |
Why?
| | Neisseria meningitidis | 1 | 2011 | 22 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1289 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2013 | 299 | 0.020 |
Why?
| | Immune Evasion | 1 | 2011 | 54 | 0.020 |
Why?
| | Bacterial Toxins | 1 | 2011 | 107 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 91 | 0.020 |
Why?
| | Locomotion | 1 | 2011 | 98 | 0.020 |
Why?
| | Virulence | 1 | 2011 | 253 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6247 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 526 | 0.020 |
Why?
| | Critical Illness | 1 | 2015 | 753 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2013 | 734 | 0.020 |
Why?
| | Rectum | 1 | 1988 | 166 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2013 | 894 | 0.020 |
Why?
| | Physical Examination | 1 | 1988 | 237 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1090 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 1523 | 0.020 |
Why?
| | Quality Improvement | 1 | 2013 | 1101 | 0.020 |
Why?
| | Abdominal Injuries | 1 | 1985 | 122 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 1985 | 283 | 0.010 |
Why?
| | Norway | 1 | 1988 | 42 | 0.000 |
Why?
| | Prognosis | 1 | 1985 | 3787 | 0.000 |
Why?
|
|
Stenehjem's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|